

Radosław Lenarczyk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4636397/publications.pdf>

Version: 2024-02-01

110
papers

8,856
citations

257450

24
h-index

42399

92
g-index

114
all docs

114
docs citations

114
times ranked

11273
citing authors

#	ARTICLE	IF	CITATIONS
1	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2733-2779.	2.2	3,469
2	2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>European Heart Journal</i> , 2015, 36, 2793-2867.	2.2	3,187
3	The Changing Landscape for Stroke Prevention in AF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 777-785.	2.8	244
4	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update. <i>Europace</i> , 2020, 22, 184-184.	1.7	160
5	Catheter Ablation of Atrial Fibrillation: An Overview for Clinicians. <i>Advances in Therapy</i> , 2017, 34, 1897-1917.	2.9	102
6	Importance of complete revascularization in patients with acute myocardial infarction treated with percutaneous coronary intervention. <i>American Heart Journal</i> , 2007, 153, 304-312.	2.7	74
7	Assessment of apical rocking: a new, integrative approach for selection of candidates for cardiac resynchronization therapy. <i>European Journal of Echocardiography</i> , 2010, 11, 863-869.	2.3	74
8	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). <i>Europace</i> , 2019, 21, 7-8.	1.7	72
9	Quality indicators for the care and outcomes of adults with atrial fibrillation. <i>Europace</i> , 2021, 23, 494-495.	1.7	64
10	Mid-term outcomes of triple-site vs. conventional cardiac resynchronization therapy: A preliminary study. <i>International Journal of Cardiology</i> , 2009, 133, 87-94.	1.7	62
11	The use of wearable cardioverter-defibrillators in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2016, 18, 146-150.	1.7	60
12	Triple-site biventricular pacing in patients undergoing cardiac resynchronization therapy: a feasibility study. <i>Europace</i> , 2007, 9, 762-767.	1.7	50
13	Effect of Anemia in High-Risk Groups of Patients With Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 611-618.	1.6	43
14	Implantation Feasibility, Procedure-Related Adverse Events and Lead Performance During 1-Year Follow-Up in Patients Undergoing Triple-Site Cardiac Resynchronization Therapy: A Substudy of TRUST CRT Randomized Trial. <i>Journal of Cardiovascular Electrophysiology</i> , 2012, 23, 1228-1236.	1.7	43
15	Effect of Type of Atrial Fibrillation on Prognosis in Acute Myocardial Infarction Treated Invasively. <i>American Journal of Cardiology</i> , 2012, 109, 1689-1693.	1.6	41
16	Use of leadless pacemakers in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2018, 20, 555-559.	1.7	41
17	Many response criteria are poor predictors of outcomes after cardiac resynchronization therapy: validation using data from the randomized trial. <i>Europace</i> , 2013, 15, 835-844.	1.7	38
18	Effect of Percutaneous Interventions within the Coronary Sinus on the Success Rate of the Implantations of Resynchronization Pacemakers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2006, 29, 1075-1080.	1.2	35

#	ARTICLE	IF	CITATIONS
19	Patients' knowledge and attitudes regarding living with implantable electronic devices: results of a multicentre, multinational patient survey conducted by the European Heart Rhythm Association. <i>Europace</i> , 2018, 20, 386-391.	1.7	35
20	Prognostic Significance of Hyperuricemia in Patients with Different Types of Renal Dysfunction and Acute Myocardial Infarction Treated with Percutaneous Coronary Intervention. <i>Nephron Clinical Practice</i> , 2010, 116, c114-c122.	2.3	34
21	Triple-Site Versus Standard Cardiac Resynchronization Therapy Study (TRUST CRT): Clinical Rationale, Design, and Implementation. <i>Journal of Cardiovascular Electrophysiology</i> , 2009, 20, 658-662.	1.7	30
22	Current perspectives on wearable rhythm recordings for clinical decision-making: the WEHRables 2 survey. <i>Europace</i> , 2021, 23, 1106-1113.	1.7	30
23	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. <i>Europace</i> , 2020, 22, 496-505.	1.7	29
24	In Heart Failure Patients with Left Bundle Branch Block Single Lead MultiSpot Left Ventricular Pacing Does Not Improve Acute Hemodynamic Response To Conventional Biventricular Pacing. A Multicenter Prospective, Interventional, Non-Randomized Study. <i>PLoS ONE</i> , 2016, 11, e0154024.	2.5	28
25	The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively. <i>Cardiovascular Diabetology</i> , 2012, 11, 78.	6.8	27
26	Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2020, 22, 162-169.	1.7	26
27	Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 1862-1867.	1.7	24
28	Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 798-806.	1.8	24
29	Mobile health applications for managing atrial fibrillation for healthcare professionals and patients: a systematic review. <i>Europace</i> , 2020, 22, 1567-1578.	1.7	23
30	Stroke and death prediction with CHA2DS2-vasc score after myocardial infarction in patients without atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 497-502.	1.5	22
31	Management of ventricular tachycardia in the ablation era: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2018, 20, 209-213.	1.7	22
32	Transseptal versus transaortic approach for radiofrequency ablation in patients with cardioverter-defibrillator and electrical storm. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2010, 28, 45-50.	1.3	21
33	Implantation of subcutaneous implantable cardioverter defibrillators in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2016, 18, 1434-1439.	1.7	21
34	Coronary sinus stenting for the stabilization of left ventricular lead during resynchronization therapy. <i>Europace</i> , 2006, 8, 367-370.	1.7	20
35	LV mechanical dispersion as a predictor of ventricular arrhythmia in patients with advanced systolic heart failure. <i>Herz</i> , 2016, 41, 599-604.	1.1	18
36	Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI). <i>Europace</i> , 2018, 20, 1218-1224.	1.7	18

#	ARTICLE	IF	CITATIONS
37	Effect of Cardiac Resynchronization on Gradient Reduction in Patients with Obstructive Hypertrophic Cardiomyopathy: Preliminary Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2011, 34, 1544-1552.	1.2	17
38	Device-related infective endocarditis in cardiac resynchronization therapy recipients – Single center registry with over 2500 person-years follow up. <i>International Journal of Cardiology</i> , 2017, 227, 18-24.	1.7	17
39	Prognostic Significance of Complex Ventricular Arrhythmias Complicating ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2018, 121, 805-809.	1.6	17
40	Contrast-induced acute kidney injury in patients undergoing cardiac resynchronization therapy – incidence and prognostic importance. Sub-analysis of data from randomized TRUST CRT trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 40, 1-8.	1.3	16
41	Long-term outcome of catheter ablation and other form of therapy for electrical storm in patients with implantable cardioverter-defibrillators. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 227-234.	1.3	16
42	Cohort profile: the ESC EURObservational Research Programme Atrial Fibrillation III (AF III) Registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 229-237.	4.0	16
43	Approach to cardio-oncologic patients with special focus on patients with cardiac implantable electronic devices planned for radiotherapy: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2017, 19, 1579-1584.	1.7	15
44	Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. <i>Europace</i> , 2018, 20, 1382-1387.	1.7	15
45	Resynchronization or Dyssynchronization? Successful Treatment with Biventricular Stimulation of a Child with Obstructive Hypertrophic Cardiomyopathy without Dyssynchrony. <i>Journal of Cardiovascular Electrophysiology</i> , 2007, 18, 542-544.	1.7	14
46	Factors influencing the use of subcutaneous or transvenous implantable cardioverter-defibrillators: results of the European Heart Rhythm Association prospective survey. <i>Europace</i> , 2018, 20, 887-892.	1.7	14
47	Factors influencing the use of leadless or transvenous pacemakers: results of the European Heart Rhythm Association Prospective Survey. <i>Europace</i> , 2020, 22, 667-673.	1.7	14
48	Utilization and perception of same-day discharge in electrophysiological procedures and device implantations: an EHRA survey. <i>Europace</i> , 2021, 23, 149-156.	1.7	14
49	Long-term outcomes of cardiac resynchronization therapy are worse in patients who require atrioventricular junction ablation for atrial fibrillation than in those with sinus rhythm. <i>Cardiology Journal</i> , 2014, 21, 309-315.	1.2	14
50	The Incremental Value of Right Ventricular Indices for Predicting Response to Cardiac Resynchronization Therapy. <i>Journal of the American Society of Echocardiography</i> , 2011, 24, 170-179.e3.	2.8	13
51	Significance of Atrial Fibrillation Complicating ST-Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2017, 120, 517-521.	1.6	13
52	The influence of age on the psychological profile of patients with cardiac implantable electronic devices: results from the Italian population in a multicenter study conducted by the European Heart Rhythm Association. <i>Aging Clinical and Experimental Research</i> , 2019, 31, 1219-1226.	2.9	13
53	Catheter ablation of atrial fibrillation: current status, techniques, outcomes and challenges. <i>Kardiologia Polska</i> , 2018, 76, 1680-1686.	0.6	13
54	Electrophysiological Features of Orthodromic Atrioventricular Reentry Tachycardia in Patients with Wolff-Parkinson-White Syndrome and Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2003, 26, 1479-1488.	1.2	12

#	ARTICLE	IF	CITATIONS
55	Can we rely on machines? Device-detected atrial high rates correspond well with atrial arrhythmias in cardiac resynchronization recipients. <i>Europace</i> , 2016, 18, 436-444.	1.7	12
56	Prognostic value of collagen turnover biomarkers in cardiac resynchronization therapy: A subanalysis of the TRUST CRT randomized trial population. <i>Heart Rhythm</i> , 2016, 13, 1088-1095.	0.7	12
57	Cryoballoon ablation of atrial fibrillation in patients with advanced systolic heart failure and cardiac implantable electronic devices. <i>Kardiologia Polska</i> , 2018, 76, 1081-1088.	0.6	12
58	Peri-procedural management, implantation feasibility, and short-term outcomes in patients undergoing implantation of leadless pacemakers: European Snapshot Survey. <i>Europace</i> , 2020, 22, 833-838.	1.7	11
59	Diagnosis, family screening, and treatment of inherited arrhythmogenic diseases in Europe: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2020, 22, 1904-1910.	1.7	11
60	Sleep apnoea as a predictor of mid- and long-term outcome in patients undergoing cardiac resynchronization therapy. <i>Europace</i> , 2008, 11, 106-114.	1.7	10
61	The impact of unsuccessful percutaneous coronary intervention on short- and long-term prognosis in STEMI and NSTEMI. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 78, 514-522.	1.7	10
62	Management of patients with ventricular arrhythmias and prevention of sudden cardiac death—translating guidelines into practice: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2018, 20, f249-f253.	1.7	10
63	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019, 21, 1116-1125.	1.7	10
64	Different Types of Renal Dysfunction in Patients with Acute Myocardial Infarction Treated with Percutaneous Coronary Intervention. <i>Journal of Interventional Cardiology</i> , 2007, 20, 143-152.	1.2	9
65	Triple site biventricular pacing in a patient with congestive heart failure and severe mechanical dyssynchrony. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2007, 18, 187-190.	1.3	9
66	Quality of Life in Cardiac Resynchronization Recipients: Association with Response and Impact on Outcome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 8-17.	1.2	9
67	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. <i>Europace</i> , 2021, 23, 314-322.	1.7	9
68	Effects of Cardiac Resynchronization Therapy on Heart Rate Turbulence. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2009, 32, S90-3.	1.2	8
69	3D and 2D left ventricular systolic function imaging – from ejection fraction to deformation. Cardiac resynchronization therapy – substudy. <i>Acta Cardiologica</i> , 2015, 70, 21-30.	0.9	7
70	The Incidence, Clinical Significance, and Treatment Effects of Depression in Cardiac Resynchronization Therapy Recipients. <i>Cardiology</i> , 2017, 138, 115-121.	1.4	7
71	Cryoablation for treatment of cardiac arrhythmias: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2017, 19, 303-307.	1.7	7
72	Importance of Dedicated Units for the Management of Patients With Inherited Arrhythmia Syndromes. <i>Circulation Genomic and Precision Medicine</i> , 2021, 14, e003313.	3.6	7

#	ARTICLE	IF	CITATIONS
73	Risk stratification for complex ventricular arrhythmia complicating ST-segment elevation myocardial infarction. <i>Coronary Artery Disease</i> , 2018, 29, 681-686.	0.7	6
74	Left ventricular scar and the acute hemodynamic effects of multivein and multipolar pacing in cardiac resynchronization. <i>IJC Heart and Vasculature</i> , 2018, 19, 14-19.	1.1	6
75	Atrial fibrillation in cardiac resynchronization recipients with and without prior arrhythmic history. How much of arrhythmia is too much?. <i>Cardiology Journal</i> , 2015, 22, 267-275.	1.2	6
76	Day by day telemetric care of patients treated with cardiac resynchronisation therapy: first Polish experience. <i>Kardiologia Polska</i> , 2016, 74, 741-748.	0.6	6
77	Do we need to monitor the percentage of biventricular pacing day by day?. <i>International Journal of Cardiology</i> , 2016, 221, 81-89.	1.7	5
78	The Impact of Routine Angiographic Follow-Up in a Population of Patients Undergoing Percutaneous Coronary Intervention Within the Left Main Coronary Artery. <i>Angiology</i> , 2016, 67, 742-748.	1.8	5
79	Upgrade from implantable cardioverter-defibrillator vs. <i>de novo</i> implantation of cardiac resynchronization therapy: long-term outcomes. <i>Europace</i> , 2021, 23, 113-122.	1.7	5
80	Efficacy of cardiac resynchronisation therapy in the treatment of end-stage inotrope-dependent heart failure patients. <i>Kardiologia Polska</i> , 2014, 72, 777-782.	0.6	5
81	Polish and European management strategies in patients with atrial fibrillation. Data from the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq1 1 0.784314 rgBT /@verlock	1.4	5
82	Trends in antithrombotic management in patients with atrial fibrillation: a report from Polish participants in the EURObservational Research Programme "Atrial Fibrillation General Long-Term Registry. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 196-205.	0.4	5
83	Evaluation of left ventricular systolic and diastolic function in patients with atrioventricular re-entrant tachycardia treated by radiofrequency current ablation. <i>Acta Cardiologica</i> , 2008, 63, 221-227.	0.9	4
84	Antithrombotic therapy for stroke prevention in patients with atrial fibrillation who survive an intracerebral haemorrhage: results of an EHRA survey. <i>Europace</i> , 2021, 23, 806-814.	1.7	4
85	Alternating left and right bundle branch block. <i>Kardiologia Polska</i> , 2014, 72, 987-987.	0.6	4
86	Outcomes in patients undergoing cardiac resynchronisation therapy complicated by device-related infective endocarditis. <i>Kardiologia Polska</i> , 2018, 76, 1525-1533.	0.6	4
87	Trying to predict the unpredictable: Variations in device-based daily monitored diagnostic parameters can predict malignant arrhythmic events in patients undergoing cardiac resynchronization therapy. <i>Cardiology Journal</i> , 2014, 21, 405-412.	1.2	4
88	Prognosis in diabetic patients with acute myocardial infarction treated invasively is related to renal function. <i>Medical Science Monitor</i> , 2010, 16, CR67-74.	1.1	4
89	The risk of stroke in patients with acute myocardial infarction treated invasively. <i>Coronary Artery Disease</i> , 2012, 23, 9-15.	0.7	3
90	Successful implantation of leadless pacemakers in children: a case series. <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.6	3

#	ARTICLE	IF	CITATIONS
91	Vascular disease in patients with atrial fibrillation. A report from Polish participants in the EORPâ€AF General Longâ€Term Registry. <i>International Journal of Clinical Practice</i> , 2021, 75, e13701.	1.7	3
92	Platelet count and volume indices in patients with contrast-induced acute kidney injury and acute myocardial infarction treated invasively. <i>Kardiologia Polska</i> , 2015, 73, 520-526.	0.6	3
93	Early therapy following myocardial infarction: arguments for and against implantable cardioverter-defibrillators. <i>Future Cardiology</i> , 2010, 6, 315-323.	1.2	2
94	Clinical manifestations of device-related infective endocarditis in cardiac resynchronization therapy recipients. <i>Archives of Medical Science</i> , 2021, 17, 638-645.	0.9	2
95	Utilization of Subcutaneous Cardioverter-Defibrillator in Poland and Europeâ€Comparison of the Results of Multi-Center Registries. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7178.	2.6	2
96	Factors determining the choice between subcutaneous or transvenous implantable cardioverter-defibrillators in Poland in comparison with other European countries: a sub-study of the European Heart Rhythm Association prospective survey. <i>Kardiologia Polska</i> , 2018, 76, 1507-1515.	0.6	2
97	Ferritin as a potential biomarker of efficacy of treatment of atrial fibrillation - preliminary report. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2017, 71, 0-0.	0.1	2
98	Patient perspective and safety of remote monitoring of implantable cardioverter-defibrillators in the Polish Nationwide Multicenter Registry: the Medtronic CareLink network evaluation. <i>Kardiologia Polska</i> , 2020, 78, 1115-1121.	0.6	2
99	Quality of life in patients with a subcutaneous vs. transvenous implantable cardioverter-defibrillator. <i>Kardiologia Polska</i> , 2022, 80, 679-684.	0.6	2
100	Influence of Reciprocating Tachycardia on the Development of Atrial Fibrillation in Patients with Preexcitation Syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, 85-92.	1.2	1
101	Sleep-disordered breathing and echocardiographic measures of function and dyssynchrony. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 886-895.	1.5	1
102	Gender-related differences in long-term outcome among high-risk patients with myocardial infarction treated invasively. <i>Postepy W Kardiologii Interwencyjnej</i> , 2017, 2, 107-116.	0.2	1
103	Doppler predictors of inducibility of atrial fibrillation in patients with WPW syndrome and atrioventricular re-entrant tachycardia. <i>Acta Cardiologica</i> , 2007, 62, 615-621.	0.9	1
104	The incidence and risk factors of stroke in patients with acute myocardial infarction treated invasively and concomitant impaired renal function. <i>Cardiology Journal</i> , 2013, 20, 672-678.	1.2	1
105	Prevention of sudden cardiac death by the implantable cardioverter-defibrillator. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 764-770.	0.4	1
106	Palmoplantar Keratoderma VÃ¶rner-Unna-Thost. , 2009, , 1560-1561.		0
107	Pacemaker endocarditis â€ did we let the genie out of the bottle? Comment on "Implantation of an epicardial lead through mini-thoracotomy as an alternative for patients with lead-related endocarditis who require permanent pacing". <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2013, 1, 65-66.	0.1	0
108	Radiofrequency catheter ablation as a treatment option in a patient with hypoplastic left heart syndrome and atrial flutter after Fontan operationâ€Case report. <i>Journal of Arrhythmia</i> , 2021, 37, 1101-1104.	1.2	0

#	ARTICLE	IF	CITATIONS
109	Sequence of electrical activation, atrial remodelling and atrial fibrillation in patients with nodal re-entrant tachycardia. <i>Acta Cardiologica</i> , 2007, 62, 599-606.	0.9	0
110	Ventricular fibrillation induced by a radiofrequency energy delivery for premature ventricular contractions arising from the right ventricular outflow tract – is ICD indicated?. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 166-170.	0.4	0